Plain-English translation of NCT06615596 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing whether people with atrial fibrillation (an irregular heart rhythm) who have had successful catheter ablation โ a procedure to fix the rhythm problem โ still need to take blood thinning medications. Researchers will randomly assign patients to either continue taking oral anticoagulants like dabigatran, rivaroxaban, or apixaban, or to stop taking these medications entirely. The study will monitor both groups for two years to see if stopping the medication is safe or if it increases the risk of stroke or bleeding.
Currently, doctors aren't sure how long patients need to take blood thinners after a successful ablation procedure. Some patients may not need them if their heart rhythm stays normal, which could reduce unnecessary bleeding risks. This study will provide clear evidence to help doctors make better decisions about post-ablation care.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be randomly assigned to either continue taking your blood thinner medication daily for 24 months or to stop taking it after joining the study. You'll wear a smart device that continuously monitors your heart rhythm to detect any irregular beats, even ones you don't feel. You'll have check-in visits at 3, 6, 12, 18, and 24 months, and your health data will be sent regularly to the research team so doctors can track whether you're having any heart rhythm problems or bleeding issues.
AI-generated summary from trial data ยท Jul 7, 2026 ยท Not medical advice
United States
China